From the world of treating disease in ways the medical community had not heard only a few short years ago, comes exciting news from out of Vancouver, Washington.
The late-stage biotech firm known as CytoDyn Inc. (OTC:CYDY) has been busy developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications. The treatment is aimed at making the lives of those with HIV more bearable.
CYDY announced significant progress Tuesday in securing the therapeutic effect and safety of leronlimab (PRO 140) with the development of an assay that can reliably determine a patient’s CCR5 status.
The way things are now, all new patients in the company’s monotherapy trial are being evaluated with this newly developed screening-level test with the objective of identifying patients expected to respond to a monotherapy versus those not expected to respond due to CCR5 density.
CEO Nader Pourhassen, "The development and implementation of an assay that can rapidly and accurately identify potential responders to leronlimab offers a tremendous technical advancement with the potential to more precisely target leronlimab on patients most likely to respond to treatment."
Shares took on four cents, or 8.4%, early Tuesday afternoon, to 52 cents, on a volume of 659,000 shares
